Pharmacokinetics (PK), Safety and Overall Response Rate (ORR) Achieved with Subcutaneous (SC) Administration of Rituximab in Combination with Chemotherapy Were Comparable to Those Achieved with Intravenous (IV) Administration in Patients (pts) with Follicular Lymphoma (FL) in the First-Line Setting: Stage 1 Results of the Phase III SABRINA Study (BO22334)

Andrew Davies,Francesco Merli,Biljana Mihaljevik,Noppadol Siritanaratkul,Philippe Solal-Céligny,Axel Boehnke,Claude Berge,Christine Mcintyre,Martin Barrett,David Macdonald

doi:10.1182/blood.v120.21.1629.1629

Pharmacokinetics (PK), Safety and Overall Response Rate (ORR) Achieved with Subcutaneous (SC) Administration of Rituximab in Combination with Chemotherapy Were Comparable to Those Achieved with Intravenous (IV) Administration in Patients (pts) with Follicular Lymphoma (FL) in the First-Line Setting: Stage 1 Results of the Phase III SABRINA Study (BO22334)

Andrew Davies, Francesco Merli + Show 8 more

https://doi.org/10.1182/blood.v120.21.1629.1629

Copy DOI

Journal: Blood	Publication Date: Nov 16, 2012
Citations: 4

Affiliation: Centre Jean Bernard, Siriraj Hospital, Queen Elizabeth II Health Sciences Centre, Roche (United Kingdom), Cancer Research UK, University of Southampton, Roche (Switzerland), Azienda Ospedaliera S.Maria

#Subcutaneous #Subcutaneous Arm + Show 8 more

Abstract
Full-Text PDF
Similar Papers

Abstract

Pharmacokinetics (PK), Safety and Overall Response Rate (ORR) Achieved with Subcutaneous (SC) Administration of Rituximab in Combination with Chemotherapy Were Comparable to Those Achieved with Intravenous (IV) Administration in Patients (pts) with Follicular Lymphoma (FL) in the First-Line Setting: Stage 1 Results of the Phase III SABRINA Study (BO22334)

Full Text